- Home
- DXR vs PPCB Comparison
DXR vs PPCB Comparison
Compare DXR & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- PPCB
- Stock Information
- Founded
- DXR 1970
- PPCB 2007
- Country
- DXR United States
- PPCB Australia
- Employees
- DXR N/A
- PPCB N/A
- Industry
- DXR Medical/Dental Instruments
- PPCB
- Sector
- DXR Health Care
- PPCB
- Exchange
- DXR Nasdaq
- PPCB Nasdaq
- Market Cap
- DXR 46.9M
- PPCB 39.1M
- IPO Year
- DXR N/A
- PPCB N/A
- Fundamental
- Price
- DXR $13.50
- PPCB $1.91
- Analyst Decision
- DXR Strong Buy
- PPCB
- Analyst Count
- DXR 1
- PPCB 0
- Target Price
- DXR $25.00
- PPCB N/A
- AVG Volume (30 Days)
- DXR 5.1K
- PPCB 316.9K
- Earning Date
- DXR 01-01-0001
- PPCB 09-30-2025
- Dividend Yield
- DXR N/A
- PPCB N/A
- EPS Growth
- DXR 3.46
- PPCB N/A
- EPS
- DXR 0.36
- PPCB N/A
- Revenue
- DXR $66,306.00
- PPCB N/A
- Revenue This Year
- DXR N/A
- PPCB N/A
- Revenue Next Year
- DXR N/A
- PPCB N/A
- P/E Ratio
- DXR $38.30
- PPCB N/A
- Revenue Growth
- DXR N/A
- PPCB N/A
- 52 Week Low
- DXR $6.55
- PPCB $1.25
- 52 Week High
- DXR $14.00
- PPCB $145.46
- Technical
- Relative Strength Index (RSI)
- DXR 66.65
- PPCB N/A
- Support Level
- DXR $13.39
- PPCB N/A
- Resistance Level
- DXR $14.00
- PPCB N/A
- Average True Range (ATR)
- DXR 0.50
- PPCB 0.00
- MACD
- DXR 0.13
- PPCB 0.00
- Stochastic Oscillator
- DXR 80.93
- PPCB 0.00
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.